Skip to main content
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. — Investor Relations & Filings

Ticker · BCAX ISIN · US0554771032 US Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2024-09-13 Capital/Financing Update
Country US United States of America
Listing US BCAX

About Bicara Therapeutics Inc.

https://www.bicara.com/

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class, dual-action biologics for cancer treatment. The company engineers bifunctional therapies that combine the precision of targeted treatments with the activation of a potent and durable anti-tumor immune response. This approach is designed to deliver therapeutic impact directly within the tumor microenvironment, with a primary focus on developing treatments for patients with solid tumors.

Recent filings

Filing Released Lang Actions
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the registrant, legal counsel, accounting firm consents, and signatures of officers and directors. The document is not an annual or quarterly report, earnings release, or any other financial performance report. It is a capital markets filing related to the registration of securities for sale to the public, which aligns with Capital/Financing Update filings. The document length is 6440 characters, which is substantive and contains the full registration statement, not just an announcement or notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-09-13 English
Regulatory Filings 2024
Regulatory Filings
2024-09-12 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 3 filed with the SEC for Bicara Therapeutics Inc. It is a preliminary prospectus related to an initial public offering (IPO) of common stock. The document includes detailed information about the offering, company overview, risk factors, use of proceeds, capitalization, management discussion and analysis, executive compensation, principal stockholders, and other disclosures typical of an IPO registration statement. This type of filing is a registration statement under the Securities Act of 1933, specifically a Form S-1/A, which is used for registering securities for public offering. It is not an annual report, earnings release, or any other report type listed in the classification scheme. Therefore, the correct classification is Regulatory Filings (RNS), as it is a general regulatory filing that does not fit into other specific categories.
2024-09-11 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is a registration statement for Bicara Therapeutics Inc. to register its common stock on The Nasdaq Stock Market. The document is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. It does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS). The document length is 3381 characters, which is relatively short and consistent with a regulatory filing form rather than a full report.
2024-09-10 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-1 for Bicara Therapeutics Inc. It discusses the distribution of the Preliminary Prospectus and requests acceleration of the effectiveness of the Registration Statement. The content is related to the process of securities registration and underwriting, not a financial report or earnings release. The document is short (2071 characters) and is a communication about a regulatory filing rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2024-09-10 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and is signed by the CEO. The content is a formal request related to the registration process for securities, not a financial report, earnings release, or other detailed filing. The document length is short (1691 characters) and it is clearly an announcement/request related to a regulatory filing process. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-09-10 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.